Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates

被引:25
作者
Jones, RN
Moet, GJ
Sader, HS
Fritsche, TR
机构
[1] JONES Grp, JMI Labs, N Liberty, IA 52317 USA
[2] Tufts Univ, Sch Med, Boston, MA 02111 USA
关键词
streptococci; enterococci; staphylococci; streptogramins; oxazolidinones;
D O I
10.1093/jac/dkh184
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To evaluate the potency of a novel peptide deformylase inhibitor, NVP PDF-713, against Gram-positive organisms having resistances to linezolid or quinupristin/dalfopristin. Materials and methods: A total of 45 strains from three genera (six species groups) were tested by reference broth microdilution methods. The mechanism of resistance to the oxazolidinone was determined by sequencing of the gene encoding the ribosomal target. Results: NVP PDF-713 retained activity against linezolid-resistant staphylococci (MIC range 0.25-2 mg/L), Streptococcus oralis (MIC 0.5 mg/L), Enterococcus faecalis (MIC range 2-4 mg/L) and Enterococcus faecium (MIC range 0.5-4 mg/L). Quinupristin/dalfopristin-resistant E. faecium (MIC range 1-2 mg/L) and staphylococci (MIC range 0.12-2 mg/L) were also inhibited by NVP PDF-713. Many (10 of 13 strains) of the linezolid-resistant enterococci were resistant to vancomycin and these clinical strains had a G2576U ribosomal target mutation. Conclusions: NVP PDF-713 appears to be a promising clinical candidate among the peptide deformylase inhibitors for the treatment of infections caused by Gram-positive organisms that possess resistances to oxazolidinones or streptogramin combinations.
引用
收藏
页码:804 / 807
页数:4
相关论文
共 17 条
[1]   Quality control guidelines for MIC susceptibility testing of NVPPDF-713: a novel peptide deformylase inhibitor [J].
Anderegg, TR ;
Biedenbach, DJ ;
Jones, RN .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2003, 22 (01) :84-86
[2]  
[Anonymous], 2003, NCCLS Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, V6th
[3]   Peptide deformylase as an antibacterial drug target:: Target validation and resistance development [J].
Apfel, CM ;
Locher, H ;
Evers, S ;
Takács, B ;
Hubschwerlen, C ;
Pirson, W ;
Page, MGP ;
Keck, W .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (04) :1058-1064
[4]   In vitro activities of nine peptide deformylase inhibitors and five comparator agents against respiratory and skin pathogens [J].
Bowker, KE ;
Noel, AR ;
MacGowan, AP .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2003, 22 (06) :557-561
[5]  
Canu A., 2001, Current Drug Targets - Infectious Disorders, V1, P215, DOI 10.2174/1568005014606152
[6]   Peptide deformylase inhibitors as antibacterial agents: Identification of VRC3375, a proline-3-alkylsuccinyl hydroxamate derivative, by using an integrated combinatorial and medicinal chemistry approach [J].
Chen, D ;
Hackbarth, C ;
Ni, ZJ ;
Wu, C ;
Wang, W ;
Jain, R ;
He, Y ;
Bracken, K ;
Weidmann, B ;
Patel, DV ;
Trias, J ;
White, RJ ;
Yuan, Z .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (01) :250-261
[7]  
CRAIG WA, 2001, 41 INT C ANT AG CHEM, P206
[8]   Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents [J].
Giglione, C ;
Pierre, M ;
Meinnel, T .
MOLECULAR MICROBIOLOGY, 2000, 36 (06) :1197-1205
[9]  
GIGLIONE C, 2001, EXPER OPIN THER TAR, V5, P415
[10]   α-substituted hydroxamic acids as novel bacterial deformylase inhibitor-based antibacterial agents [J].
Jain, R ;
Sundram, A ;
Lopez, S ;
Neckermann, G ;
Wu, C ;
Hackbarth, C ;
Chen, D ;
Wang, W ;
Ryder, NS ;
Weidmann, B ;
Patel, D ;
Trias, J ;
White, R ;
Yuan, Z .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (23) :4223-4228